// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Clinical effectiveness and models of pulmonary rehabilitation in low-resource-settings: a systematic review

Monsur Habib - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

An integrated nurse-led community home oxygen service (HOS) improves patient centred working and experience and reduces costs

Glenda Esmond - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

UK Opinions on provision of Home Oxygen in current smokers

Claire Davey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Experiences of staff involved in delivering a novel breathlessness rehabilitation service: results from qualitative focus groups

Linzy Houchen-Wolloff - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cognitive impairment (CI) and pulmonary rehabilitation (PR) in COPD

Mark Orme - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The Hospital Anxiety and Depression Scale (HADS) in Bronchiectasis: Response to pulmonary rehabilitation (PR) and Minimum Clinically Important Difference (MCID)

Stephanie Wynne - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

The incremental shuttle walk test (ISW) in patients with bronchiectasis: Response to pulmonary rehabilitation (PR) and minimum clinically important difference (MCID)

Jessica Walsh - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Gait speed and mortality in chronic obstructive pulmonary disease (COPD)

Jessica A Walsh - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation?

Sarah Edwards - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Profiling changes in physical activity and exercise capacity following lifestyle interventions in COPD

Tareq Alotaibi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Does daily physical activity levels or functional exercise capacity provide additional prognostic information in idiopathic pulmonary fibrosis (IPF)?

Suhani Patel - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Progression of physical inactivity in COPD patients: the effect of time and climate conditions – a multicentre prospective cohort study

Afroditi Boutou - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The effect of pulmonary rehabilitation (PR) on anxiety and depression symptoms in bronchiectasis: a propensity-matched study

Stephanie Wynne - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Depression

N/A

Physical activity (PA) and exercise participation during pulmonary rehabilitation (PR)

Sarah Ward - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The RECHARGE database: Towards a global standard for pulmonary rehabilitation (PR)

Robert C Free - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review

Sandip Banerjee - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Patient and public involvement and application of the Behaviour Change Wheel to promote physical activity following pulmonary rehabilitation in COPD: an intervention development study

Hayley Robinson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Prediction of muscle weakness in COPD: results from modelling using the ERICA cohort

Necdet Gunsoy - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Pulmonary rehabilitation (PR) in adults with COPD and Heart Failure (HF); data from the UK 2015 National COPD:PR Audit

Amy Jones - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Congestive heart failure

N/A

Group-Based social identity intervention during pulmonary rehabilitation improves COPD patients experience with exercise programmes

Samantha Pilsworth - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Copyright © 2026. QuantiNova All rights reserved